TY - JOUR
T1 - Developmental therapeutics in childhood cancer
T2 - A perspective from the children's oncology group and the US Food and Drug Administration
AU - Bernstein, Mark L.
AU - Reaman, Gregory H.
AU - Hirschfeld, Steven
PY - 2001/8
Y1 - 2001/8
N2 - Drug development in pediatric oncology has been reviewed, concentrating on overall development issues and COG studies of cytotoxic compounds. A variety of interesting molecules with more specific targeting are becoming available. The challenges that remain include the availability of such compounds for pediatric trial and their study in a timely fashion, and the subsequent incorporation of the new agents into more up-front regimens, with the ultimate shared goal of curing more children with less toxicity.
AB - Drug development in pediatric oncology has been reviewed, concentrating on overall development issues and COG studies of cytotoxic compounds. A variety of interesting molecules with more specific targeting are becoming available. The challenges that remain include the availability of such compounds for pediatric trial and their study in a timely fashion, and the subsequent incorporation of the new agents into more up-front regimens, with the ultimate shared goal of curing more children with less toxicity.
UR - http://www.scopus.com/inward/record.url?scp=0034793582&partnerID=8YFLogxK
U2 - 10.1016/S0889-8588(05)70240-9
DO - 10.1016/S0889-8588(05)70240-9
M3 - Article
C2 - 11676277
AN - SCOPUS:0034793582
SN - 0889-8588
VL - 15
SP - 631
EP - 655
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 4
ER -